Short answer
Aquestive Therapeutics, Inc. (AQST) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $14M (up 65.7% year over year) with net income of −$8M.
Q1 2026 key financials · XBRL
- Revenue
- $14M
- +65.7% YoY
- Net income
- −$8M
- +64.9% YoY
- Operating margin
- -29.1%
- EPS (diluted)
- −$0.07
- +70.8% YoY
Source: XBRL data from the Aquestive Therapeutics, Inc. (AQST) Q1 2026 10-Q on SEC EDGAR. USD.
Aquestive Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Third-party API manufacturing risk, newly detailed; supplier failure could delay trials or commercial supply
- FDA facility-compliance risk; failed inspections or impurities could delay approval or increase operating expenses
- Geopolitical supply disruption risk; Ukraine, Russia, Israel-Gaza, and Iran events could constrain manufacturing resources
- Single-manufacturer concentration risk; interrupted supply from one approved API manufacturer could significantly disrupt commercial availability
- Supply-switching risk; alternative manufacturers may require additional regulatory studies and delay clinical or commercial timelines
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aquestive Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.